The phageome of patients with ulcerative colitis treated with donor fecal microbiota reveals markers associated with disease remission

Nat Commun. 2024 Oct 17;15(1):8979. doi: 10.1038/s41467-024-53454-4.

Abstract

Bacteriophages are influential within the human gut microbiota, yet they remain understudied relative to bacteria. This is a limitation of studies on fecal microbiota transplantation (FMT) where bacteriophages likely influence outcome. Here, using metagenomics, we profile phage populations - the phageome - in individuals recruited into two double-blind randomized trials of FMT in ulcerative colitis. We leverage the trial designs to observe that phage populations behave similarly to bacterial populations, showing temporal stability in health, dysbiosis in active disease, modulation by antibiotic treatment and by FMT. We identify a donor bacteriophage putatively associated with disease remission, which on genomic analysis was found integrated in a bacterium classified to Oscillospiraceae, previously isolated from a centenarian and predicted to produce vitamin B complex except B12. Our study provides an in-depth assessment of phage populations during different states and suggests that bacteriophage tracking has utility in identifying determinants of disease activity and resolution.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Bacteriophages* / genetics
  • Bacteriophages* / isolation & purification
  • Bacteriophages* / physiology
  • Biomarkers
  • Colitis, Ulcerative* / microbiology
  • Colitis, Ulcerative* / therapy
  • Colitis, Ulcerative* / virology
  • Double-Blind Method
  • Dysbiosis / microbiology
  • Dysbiosis / therapy
  • Fecal Microbiota Transplantation*
  • Feces* / microbiology
  • Feces* / virology
  • Female
  • Gastrointestinal Microbiome* / genetics
  • Humans
  • Male
  • Metagenomics / methods
  • Middle Aged
  • Remission Induction
  • Virome / genetics

Substances

  • Anti-Bacterial Agents
  • Biomarkers